DelveInsight’s, “Thalassemia Pipeline Insight, 2023” report provides comprehensive insights about 30+ Thalassemia companies and 30+ pipeline drugs in Thalassemia pipeline landscape. It covers the pipeline drug profiles, including Thalassemia clinical trial and nonclinical stage products. Thalassemia pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Thalassemia Pipeline Report
Explore more about the latest breakthroughs of the Thalassemia Treatment Landscape report @ Thalassemia Pipeline Outlook
Thalassemia Overview
Thalassemia is a blood disorder that is inherited. This means it is passed down from one or both parents through their genes. When a person has thalassemia, the body makes less hemoglobin than normal. Hemoglobin is an iron-rich protein in red blood cells. It carries oxygen to all parts of the body. There are 2 main types of thalassemia: alpha and beta. Different genes are affected for each type. Thalassemia can cause mild or severe anemia. Anemia occurs when the body does not have enough red blood cells or hemoglobin. The severity and type of anemia depends on how many genes are affected. Alpha thalassemia occurs when some or all of the 4 genes that make hemoglobin (the alpha-globin genes) are missing or damaged. There are 4 types of alpha thalassemia: Alpha thalassemia silent carrier: One gene is missing or damaged, and the other 3 are normal. Alpha thalassemia carrier: Two genes are missing. Hemoglobin H disease: Three genes are missing. This leaves just 1 working gene. Alpha thalassemia major. All 4 genes are missing. This causes severe anemia. In most cases, a baby with this condition will die before birth. This is a genetic disease inherited from one or both parents.
Recent Developmental Activities in the Thalassemia Treatment Landscape
Learn more about the Thalassemia emerging therapies @ Thalassemia Ongoing Clinical Trials Analysis
Thalassemia Emerging Drugs Profile
CTX-001: CRISPR Therapeutics
CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from β-thalassemia and sickle cell disease. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Beta-Thalassemia.
Mitapivat: Agios Pharmaceuticals
Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase R (PKR) enzymes. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Transfusion-dependent Alpha or Beta Thalassemia.
DST-0509: DisperSol Technologies
DST-0509, is an investigational drug being developed by DisperSol Technologies. It belongs, to the class of antianaemics.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Thalassemia.
Thalassemia Therapeutic Assessment
There are approx. 30+ key Thalassemia companies which are developing the therapies for Thalassemia. The companies which have their Thalassemia drug candidates in the most advanced stage, i.e. phase III include, CRISPR Therapeutics.
Dive deep into rich insights for new drugs for thalassemia key players and drugs; visit @ Thalassemia Treatment Landscape
Scope of the Thalassemia Pipeline Report
Table of Content
For further information on the thalassemia pipeline therapeutics, reach out to Thalassemia Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/